Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape

European Urology, Supplements

Volumn 8, Issue 10, 2009, Pages 787-792

  Bracarda, Sergio ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Epidemiology; Metastatic renal cell carcinoma; Overall survival; Prognostic factors; Progression free survival; Targeted therapy

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; OBESITY; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70349330474     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.07.007     Document Type: Review

References (47)

1. International Agency for Research on Cancer. GLOBOCAN database 2002. CANCERMondial Web site. http://www-dep.iarc.fr/. Accessed June 2009.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 2009.
3. Gupta K., Miller J.D., Li J.Z., Russell M.W., and Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008) 193-205
4. Mathew A., Devesa S.S., Fraumeni Jr. J.F., and Chow W.H. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11 (2002) 171-178
5. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
6. American Cancer Society. Estimated new cancer cases and deaths by sex, US, 2008. American Cancer Society Web site. http://www.cancer.org/downloads/stt/CFF2008Table_pg4.pdf. Accessed June 2009.
7. Levi F., Ferlay J., Galeone C., et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 101 (2008) 949-958
8. Chow W.H., Linehan W.M., and Devesa S.S. Re: rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 99 (2007) 569-570
9. Hollingsworth J.M., Miller D.C., Daignault S., and Hollenbeck B.K. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98 (2006) 1331-1334
10. Athar U., and Gentile T.C. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 15 (2008) 3954-3966
11. Lipworth L., Tarone R.E., and McLaughlin J.K. The epidemiology of renal cell carcinoma. J Urol 176 (2006) 2353-2358
12. van Dijk B.A., Schouten L.J., Oosterwijk E., et al. Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. Br J Cancer 95 (2006) 374-377
13. Pavlovich C.P., Schmidt L.S., and Phillips J.L. The genetic basis of renal cell carcinoma. Urol Clin North Am 30 (2003) 437-454 vii
14. Gago-Dominguez M., Yuan J.M., Castelao J.E., Ross R.K., and Yu M.C. Family history and risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 10 (2001) 1001-1004
15. Negri E., Foschi R., Talamini R., et al. Family history of cancer and the risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 2441-2444
16. Linehan W.M., Vasselli J., Srinivasan R., et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10 (2004) 6282S-6289S
17. Costa L.J., and Drabkin H.A. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12 (2007) 1404-1415
18. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
19. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
20. Figlin R.A. Renal cell carcinoma: management of advanced disease. J Urol 161 (1999) 381-386
21. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
22. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
23. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
24. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
25. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
26. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
27. Nguyen C.T., and Campbell S.C. Staging of renal cell carcinoma: past, present, and future. Clin Genitourin Cancer 5 (2006) 190-197
28. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
29. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13 (2002) 1460-1468
30. Atzpodien J., Royston P., Wandert T., and Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88 (2003) 348-353
31. Guinan P., Sobin L.H., and Algaba F. TNM staging for renal cell carcinoma: workgroup no. 3 - Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 992-993
32. Zisman A., Pantuck A.J., Figlin R.A., and Belldegrun A.S. Validation of the UCLA integrated staging system for patients with renal cell carcinoma. J Clin Oncol 19 (2001) 3792-3793
33. Karakiewicz P.I., Briganti A., Chun F.K., et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25 (2007) 1316-1322
34. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110 (2007) 543-550
35. Iimura Y., Saito K., Fujii Y., et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181 (2009) 1004-1012
36. Motzer R.J., Bukowski R.M., Figlin R.A., et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113 (2008) 1552-1558
37. George S., and Bukowski R.M. Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 7 (2007) 1737-1747
38. Golshayan A.R., Brick A.J., and Choueiri T.K. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 4 (2008) 85-92
39. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008:CD006017.
40. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 25 (2007) Abstract 5023
41. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
42. Bast R.C., Thigpen J.T., Arbuck S.G., et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107 (2007) 173-176
43. Ng R., Pond G.R., Tang P.A., MacIntosh P.W., Siu L.L., and Chen E.X. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 19 (2008) 481-486
44. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 26 (2008) Abstract 5024
45. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
46. Knox J.J. Progression-free survival as endpoint in metastatic RCC?. Lancet 372 (2008) 427-429
47. Gore M.E., and Escudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park) 20 (2006) 19-24